ERBB2 and neoplasm: The HER2-targeted bispecific antibody zanidatamab demonstrated promising anti-tumor activity in a phase 2b trial (HERIZON-BTC-01, NCT04466891) among patients with HER2-amplified locally advanced or metastatic CCA [150].